Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis

Zhao, Xiangyu; Chen, Yuxing; Sun, Xiaoqin; He, Zaoke; Wu, Tao; Wu, Chengquan; Chen, Jing; Wang, Jinyu; Diao, Kaixuan; Liu, Xue Song

doi:10.3390/cancers14174226

Cited by 6 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EFNA4 expression was upregulated in various tumor types. High EFNA4 expression was associated with poor outcomes in multiple tumor types, which was consistent with previous results in liver hepatocellular carcinoma and lung adenocarcinoma (7,9). Meanwhile, EFNA4 was found to correlate with the immune landscape of the tumor microenvironment in various tumors.…”

Section: Discussionsupporting

confidence: 90%

“…Anti-EFNA4-ADC (PF-06647263) has demonstrated e cacy in the treatment of triple-negative breast cancer and ovarian serous cystadenocarcinoma(8). An increase in the copy number of EFNA4 promotes tumor cell proliferation and lymph node metastasis in lung adenocarcinoma (9). In addition, EFNA4 is involved in tumor proliferation and progression in oral squamous cell carcinoma (10).…”

mentioning

confidence: 99%

See 1 more Smart Citation

EFNA4 as a potential prognostic biomarker and therapeutic target for GBMLGG

Tang,

Zhang,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Ephrin-A4 (EFNA4) is present in numerous tissues and is connected to the growth and development of multiple types of cancer. The differences in EFNA4 expression in various types of cancer and its impact on glioblastoma and low-grade glioma (GBMLGG) are not well understood. This research seeks to determine the prognostic value of EFNA4 in predicting the outcomes of GBMLGG and to examine the role of EFNA4 in tumorigenesis in GBMLGG. Methods The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were used to examine the differential expression and genetic alterations of EFNA4, and their relationship with patient survival in 33 cancer types. Multiple algorithms were used to examine the correlation between EFNA4 expression and the infiltration of cancer-associated fibroblasts, the immune infiltration landscape, expression of immunomodulatory genes, tumor mutational burden (TMB), and the microsatellite instability (MSI) score of GBMLGG. Univariate and multivariate Cox regression models and a nomogram were developed to forecast the outcomes of patients with GBMLGG. We also established protein-protein interaction networks, identified related functional signaling pathways, and conducted drug sensitivity analyses to examine the role of EFNA4 in the progression of GBMLGG. Results In most types of cancer, there was an increase in EFNA4 mRNA expression, which was found to be associated with prognosis. The expression of EFNA4 had a positive correlation with cancer-associated fibroblast infiltration levels in various cancer types, and the levels of EFNA4 expression were markedly elevated in tumor tissues in comparison to normal tissues in GBMLGG. Overexpression of EFNA4 was significantly correlated with tumor progression, a poor prognosis, and high immune scores in GBMLGG. The nomogram and EFNA4 expression status demonstrated their ability to accurately predict the outcomes of patients with GBMLGG. Moreover, it was discovered that the expression of EFNA4 had a considerable correlation with the expression of immunomodulatory genes and biological processes such as immune cell infiltration, the tyrosine kinase signaling pathway, neurotransmitter transmission between synapses, and epithelial-mesenchymal transition in GBMLGG. Conclusions The findings of this research indicate that EFNA4 has great potential as both a prognostic biomarker and a target for the therapy for GBMLGG.

show abstract

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 99%

EFNA4 as a potential prognostic biomarker and therapeutic target for GBMLGG

Tang,

Zhang,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…We validated that hyperthermia reduced EFNA4 expression in GEM-resistant cell lines. EFNA4 has been implicated as a tumor promoter in various malignancies, including lung cancer [ 32 ], gastric cancer [ 15 ], hepatocellular carcinoma [ 33 ], and breast and ovarian cancers [ 34 ]. In PAAD, EFNA4 has also been identified as an important prognostic factor associated with shortened patient survival [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and activating dCK

He,

Zheng,

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…EFNA4, a member of the ephrin (EPH) family and encoded Ephrin A4 as the ligand for Eph receptors. It was upregulated in lung cancer patients with LNM and overexpression of EFNA4 contributed to the proliferation, migration and adhesion of lung tumor cells [ 57 ].…”

Section: Main Signaling Factors and Their Receptors Of Lymphangiogene...mentioning

confidence: 99%

Advances in lymphatic metastasis of non-small cell lung cancer

Zhang,

Ma,

Xue

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Lung cancer is a deeply malignant tumor with high incidence and mortality. Despite the rapid development of diagnosis and treatment technology, abundant patients with lung cancer are still inevitably faced with recurrence and metastasis, contributing to death. Lymphatic metastasis is the first step of distant metastasis and an important prognostic indicator of non-small cell lung cancer. Tumor-induced lymphangiogenesis is involved in the construction of the tumor microenvironment, except promoting malignant proliferation and metastasis of tumor cells, it also plays a crucial role in individual response to treatment, especially immunotherapy. Thus, this article reviews the current research status of lymphatic metastasis in non-small cell lung cancer, in order to provide some insights for the basic research and clinical and translational application in this field.

show abstract

Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis

Cited by 6 publications

References 36 publications

EFNA4 as a potential prognostic biomarker and therapeutic target for GBMLGG

EFNA4 as a potential prognostic biomarker and therapeutic target for GBMLGG

Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and activating dCK

Advances in lymphatic metastasis of non-small cell lung cancer

Contact Info

Product

Resources

About